Is Intensity Therapeutics, Inc. (INTS) a Buy, Sell, or Hold?
Intensity Therapeutics, Inc.
NASDAQ:INTS
$4.87 USD
-$0.05 (-1.02%)
- Volume
- 53.34K
- Average Volume
- 42.14K
- Market Capitalization
- $9.18M
- P/E Ratio
- -0.70
- Dividend Yield
- 0.00%
- Price Target
- $125.00
- Year High
- $43.50
- Year Low
- $3.51
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.86
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Lewis H. Bender |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | INTS |
| CUSIP | 45828J202 |
| CIK | 0001567264 |
| Web | https://www.intensitytherapeutics.com |
| Phone | 203 221 7381 |
| Currency | USD |
| Employees | 16 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.86 |
| Quick Ratio | 4.86 |
| Cash Ratio | 4.57 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.36 |
| Price / Cash Flow | -1.01 |
| Price / Book | 12.37 |
Price Target and Rating
| Average Stock Price Forecast | $125.00 |
| High Stock Price Forecast | $125.00 |
| Low Stock Price Forecast | $125.00 |
| Forecast Upside/Downside | -96.10% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 3 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-8.56 |
| Trailing P/E Ratio | -0.70 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-11.61M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -136.82% |
| Return on Assets | -87.00% |
Financials Score
| AltmanZ Score | -8.82 |
| Piotroski Score | 2.00 |
| Working Capital | 8.66M |
| Total Assets | 12.29M |
| Ebit | -10.69M |
| Market Cap | 9.28M |
| Total Liabilities | 2.31M |
Poll Results
About Intensity Therapeutics, Inc. (NASDAQ:INTS) Stock
Intensity Therapeutics, Inc. is a biotechnology enterprise in the clinical development phase, dedicated to discovering, advancing, and commercializing pharmaceutical treatments for solid tumor cancers. The company's primary experimental compound, INT230-6, is presently undergoing Phase 2 clinical trials. This investigational drug targets a range of difficult-to-treat solid tumors, including those affecting the pancreas, colon, bile duct, as well as squamous cell, sarcoma, breast, and liver cancers. Intensity Therapeutics has formed strategic collaborations with major pharmaceutical companies and research institutions: A partnership with Merck Sharpe & Dohme Corp. focuses on evaluating INT230-6 in conjunction with Keytruda for advanced pancreatic, colon, squamous cell, and bile duct maligna ... ncies. Another collaboration with Bristol-Myers Squibb Company is dedicated to studying INT230-6 combined with Yervoy in patients suffering from advanced liver, breast, and sarcoma cancers. Furthermore, the company is working with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research on a randomized controlled Phase II neoadjuvant study of INT230-6 for women diagnosed with early-stage breast cancer. Established in 2012, Intensity Therapeutics maintains its corporate headquarters in Westport, Connecticut.
2026-07-01 08:00:00
Late-stage clinical studies advancing in soft tissue sarcoma and presurgical triple-negative breast cancer Over 200 patients enrolled in completed INT230-6 studies with a peer-reviewed paper published Active strategic partnering initiatives supported by maturing INT230-6 clinical and regulatory profile Strengthened balance sheet supporting disciplined clinical development strategy SHELTON, Conn., July 1, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, today provides a mid-year update highlighting the Company's late-stage development programs and growing strategic partnering focus for INT230-6.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why
2026-05-27 13:01:10
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
2026-05-14 08:00:00
Company receives the Cancer Treatment Technology Innovator of the Year award SHELTON, Conn., May 14, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 GHP Magazine Healthcare & Pharmaceutical Awards as the Cancer Treatment Technology Innovator of the Year 2026 – USA award recipient.
Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-07 16:06:00
Cash and cash equivalents of $10.2 million as of March 31, 2026 Favorable efficacy and safety reported in a small sample of triple negative breast cancer ("TNBC") patients receiving INT230-6 prior to the standard of care ("SOC") compared to SOC alone in the INVINCIBLE-4 Study (as defined below) Approval to resume enrollment obtained in the INVINCIBLE-4 Study; plans to resume enrollment in the second quarter of 2026 Decision to resume enrollment in a limited number of U.S. sites in the INVINCIBLE-3 Study (as defined below) by the third quarter of 2026 SHELTON, Conn., May 7, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of novel intratumoral cancer therapies that are designed to kill tumors and increase immune system recognition of cancers using its proprietary non-covalent conjugation technology, announces first quarter 2026 financial results and provides a corporate update.
2026-05-01 10:56:14
Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's What You Should Know
2026-04-16 13:01:04
Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Intensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
2026-04-15 09:15:00
Company receives the Platinum Award for Innovator in Biotech Solutions Category SHELTON, Conn., April 15, 2026 /PRNewswire/ -- Intensity Therapeutics, Inc., (Nasdaq: INTS) ("Intensity" or the "Company"), a late-stage clinical biotechnology company focused on the discovery and development of proprietary cancer therapies using its non-covalent, drug-conjugation technology that creates drug products designed to kill tumors and increase immune system recognition of cancers, announces it has been named a winner of the 2026 Pinnacle Awards for Healthcare for its intratumoral injection platform and lead drug candidate INT230-6.
Frequently Asked Questions
-
What is the current Intensity Therapeutics, Inc. (INTS) stock price?
-
Intensity Therapeutics, Inc.(NASDAQ:INTS) stock price is $4.87 in the last trading session. During the trading session, INTS stock reached the peak price of $43.5 while $3.51 was the lowest point it dropped to. The percentage change in INTS stock occurred in the recent session was --1.02% while the dollar amount for the price change in INTS stock was -$-0.05.
-
INTS's industry and sector of operation?
-
The NASDAQ listed INTS is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INTS?
-
Joseph Talamo | Chief Financial Officer
Lewis H. Bender | Founder, President, Chief Executive Officer & Chairman of the Board
James Ahlers | Executive Vice President of Corporate Finance
John Wesolowski | Principal Accounting Officer & Controller
| -
How many employees does INTS have?
-
Number of INTS employees currently stands at 16. INTS operates from 61 Wilton Road, Westport, CT 06880, US.
-
Link for INTS official website?
-
Official Website of INTS is: https://www.intensitytherapeutics.com
-
How do I contact INTS?
-
INTS could be contacted at phone #203 221 7381 and can also be accessed through its website. INTS operates from 61 Wilton Road, Westport, CT 06880, US.
-
How many shares of INTS are traded daily?
-
The average number of INTS shares traded daily for last 3 months was 42.14K.
-
What is the market cap of INTS currently?
-
The market value of INTS currently stands at $9.18M with its latest stock price at $4.87